Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02162446 | 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET | completed | Phase 1 / Phase 2 | 12 | IpsenINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT04107142 | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | unknown | Phase 1 | 10 | CytoMed Therapeutics Pte LtdINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT03738111 | Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 | 0 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Sep 25, 2019 | clinicaltrials |
| NCT01758731 | Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History | completed | Phase 1 | 17 | University of Colorado, DenverOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT02814461 | The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC | completed | Phase 1 | 9 | Shin Kong Wu Ho-Su Memorial HospitalOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT02843607 | Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01259089 | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | completed | Phase 1 | 43 | Curis, Inc.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT02395250 | Anti-GPC3 CAR T for Treating Patients With Advanced HCC | completed | Phase 1 | 13 | RenJi HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03993743 | A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 34 | Xijing HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours | terminated | Phase 1 / Phase 2 | 92 | AHS Cancer Control AlbertaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02583477 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 1 / Phase 2 | 23 | AstraZenecaINDUSTRY | 2 | Aug 14, 2019 | clinicaltrials |
| NCT02949895 | Study of BMS-986012 in Subjects With Small Cell Lung Caner | completed | Phase 1 | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 12, 2019 | clinicaltrials |
| NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2019 | clinicaltrials |
| NCT03014297 | Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression | terminated | Phase 1 | 17 | Lowell Anthony, MDOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01433172 | Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer | completed | Phase 1 / Phase 2 | 73 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT02473731 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | completed | Phase 1 | 12 | Celldex TherapeuticsINDUSTRY | 1 | Aug 1, 2019 | clinicaltrials |
| NCT02707328 | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) | terminated | Phase 1 | 30 | The Cooper Health SystemOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01739439 | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery | terminated | Phase 1 | 6 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT04035876 | Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | unknown | Phase 1 / Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT01028885 | MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate | completed | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT04032392 | Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells | unknown | Phase 1 | 20 | Beijing 302 HospitalOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT00005851 | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT02389751 | Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT02179970 | To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers(CAM-PLEX) | completed | Phase 1 | 26 | CCTU- Cancer ThemeOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00079430 | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 113 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2019 | clinicaltrials |
| NCT01459380 | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Jul 22, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B | withdrawn | Phase 1 / Phase 2 | 0 | Alan KatzOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT01281852 | Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | terminated | Phase 1 / Phase 2 | 13 | PrECOG, LLC.OTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT03349255 | Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma | terminated | Phase 1 | 3 | Aeon Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT01016769 | Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) | completed | Phase 1 / Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | terminated | Phase 1 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2019 | clinicaltrials |
| NCT03057509 | A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | Jun 21, 2019 | clinicaltrials |
| NCT03167853 | Study of JS001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 40 | Peking UniversityOTHER | 1 | Jun 21, 2019 | clinicaltrials |
| NCT03652233 | Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jun 20, 2019 | clinicaltrials |
| NCT01026623 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Hitendra PatelOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT01064921 | Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma | completed | Phase 1 | 27 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03971214 | PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer(PICARES) | unknown | Phase 1 | 6 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03966209 | Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | May 31, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Oct 2, 2019source: clinicaltrials